European Leukemia Trial Registry
Trial: EWALL-PH-02

More Details
Title Study of induction and consolidation therapy with Nilotinib in combination with chemotherapy in older patients with Ph/BCR-ABL+ ALL
Scientific Title An open label phase II study to evaluate the efficacy and safety of induction and consolidation therapy with Nilotinib in combination with chemotherapy in patients aged 55 years and over with Philadelphia chromosome positive (Ph+ or BCR-ABL+) acute lymphoblastic leukemia (ALL).
Short Title EWALL-PH-02
Trialgroup EWALL
Type of Trial multicentric, open-label
Disease Acute lymphoblastic leukemia(ALL) Ph/BCR ABL +
Age >=55 years
Status No longer recruiting
Start of Recruitment 01.08.2011
Leader Ottmann, Prof. Dr., Oliver
Contactperson

Study assistance
Hermann, Julian
Tel: +49 (0)69 6301-87146
Fax: +49 (0)69 6301-7463
Email: hermann@med.uni-frankfurt.de

Centre of Trial Universitätsklinikum Frankfurt
Shortprotocol Shortprotocol
Diagnostics

MRD-Analysis
Molekulargenetik-Labor der Med.Klinik II, Universitätsklinikum Frankfurt

created 13.04.2011 Johannes Kraus
changed 11.09.2015 Zena Krüger
© ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org